Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative HSCT for Immunologic or Histiocytic Disorders
NCT00176865Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2002
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine, melphalan, antithymocyte globulin rabbit and alemtuzumab in hemophagocytic lymphohistiocytosis (HLH), Langerhans cell histiocytosis (LCH), X-linked lymphoproliferative syndrome (XLP) and 6 more (3 arms), sponsored by Masonic Cancer Center. Primary endpoint: Number of Subjects With Mixed Chimerism at Day 100. Started Aug 2002; status: completed.
02
Drugs
fludarabinemelphalanantithymocyte globulin rabbitalemtuzumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)Langerhans cell histiocytosis (LCH)X-linked lymphoproliferative syndrome (XLP)Chediak-Higashi syndrome (CHS)Griscelli syndrome (GS)
Beyond the preview
Go deeper on NCT00176865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176865.